Sex steroid hormones and genetic susceptibility to breast and prostate cancer

Drug Metabolism Reviews

Volumn 30, Issue 2, 1998, Pages 421-434

  Feigelson, Heather Spencer ^a   Ross, Ronald K ^a   Yu, Mimi C ^a   Coetzee, Gerhard A ^b   Reichardt, Juergen K V ^b   Henderson, Brian E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CYTOCHROME P450 ISOENZYME; ESTROGEN RECEPTOR; SEX HORMONE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE 17BETA DEHYDROGENASE;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER MODEL; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; ENZYME ACTIVITY; GENE ISOLATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HORMONAL REGULATION; HUMAN; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; PROSTATE CANCER; RECEPTOR GENE; RISK ASSESSMENT;

EID: 0031859124     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.3109/03602539808996320     Document Type: Conference Paper

References (39)

1. S. L. Parker, T. Tong, S. Bolden, and P. A. Wingo, Cancer statistics, 1997, Ca Cancer J. Clin., 47, 5-27 (1997).
2. B. E. Henderson, R. K. Ross, M. C. Pike, and J. T. Casagrande, Endogenous hormones as a major factor in human cancer, Cancer Res., 42, 3232-3239 (1982).
3. B. E. Henderson, R. K. Ross, and M. C. Pike, Hormonal chemo-prevention of cancer in women, Science, 259, 633-638 (1993).
4. P. Vineis, Epidemiological models of carcinogenesis: the example of bladder cancer, Cancer Epidemiol. Biomarkers Prev., 1, 149-153 (1992).
5. B. E. Henderson, V. Gerkins, I. Rosario, J. T. Casagrande, and M. C. Pike, Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer, N. Engl. J. Med., 293, 790-795 (1975).
6. L. Bernstein, J. M. Yuan, R. K. Ross, M. C. Pike, R. Hanisch, R. Lobo, F. Stanczyk, Y. T. Gao, and B. E. Henderson, Serum hormone levels in premenopausal Chinese women in Shanghai and white women in Los Angeles: Results from two breast cancer case-control studies, Cancer Causes Cont., 1, 51-58 (1990).
7. H. Shimizu, R. K. Ross, L. Berstein, M. C. Pike, and B. E. Henderson, Serum oestrogen levels in postmenopausal women: Comparison of American whites and Japanese in Japan, Br. J. Cancer, 62, 451-453 (1990).
8. P. England, L. Skinner, K. Cottrell, and R. A. Sellwood, Serum oestradiol-17β in women with benign and malignant breast disease, Br. J. Cancer, 30, 571-576 (1974).
9. S. T. Brentano, J. Picado-Leonard, S. H. Mellon, C. C. D. Moore, and W. L. Miller, Tissue-specific, cyclic adenosine 3′,5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells, Molec. Endocrinol., 4, 1972-1979 (1990).
10. A. H. Carey, D. Waterworth, K. Patel, D. White, J. Little, P. Novelli, S. Franks, and R. Willamson, Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17, Human Molec. Genet., 3, 1873-1876 (1994).
11. J. T. Kadonaga, K. A. Jones, and R. Tjian, Promoter-specific activation of RNA polymerase II transcription by SpI, Trends Biochem. Sci., 11, 20-23 (1986).
12. H. S. Feigelson, G. A. Coetzee, L. N. Kolonel, R. K. Ross, and B. E. Henderson, A polymorphism in the CYP17 gene increases the risk of breast cancer, Cancer Res., 57, 1063-1065 (1997).
13. M. Poutanen, V. Isomaa, V.-P. Lehto, and R. Vihko, Immunological analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue, Int. J. Cancer, 50, 386-390 (1992).
14. T. Normand, S. Narod, F. Labrie, and J. Simard, Detection of polymorphisms in the estradiol 17β-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21, Human Molec. Genet., 2, 479-483 (1993).
15. A. Mannermaa, H. Peltoketo, R. Winqvist, B. A. J. Ponder, H. Kiviniemi, D. F. Easton, M. Poutanen, V. Isomaa, and R. Vihko, Human familial and sporadic breast cancer: analysis of the coding regions of the 17β-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay, Human Genet., 93, 319-324 (1994).
16. T. J. Puranen, M. H. Poutanen, H. E. Peltoketo, P. T. Vihko, and R. K. Vihko, Site-directed mutagenesis of the putative active site of human 17β-hydroxysteroid dehydrogenase type 1, Biochem. J., 304, 289-293 (1994).
17. A. Castagnoli, I. Maestri, F. Bernardi, and L. Del Senno, PvuII RFLP inside the human estrogen receptor gene, Nucl. Acids Res., 15, 866 (1987).
18. T. Garcia, M. Sanchez, J. L. Cox, P. A. Shaw, J. B. A. Ross, S. Lehrer, and B. Schachter, Identification of a variant form of the human estrogen receptor with an amino acid replacement, Nucl. Acids Res., 77, 8364 (1989).
19. T. I. Andersen, K. R. Heimdal, M. Skrede, K. Tveit, K. Berg, and A. L. Borresen, Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility, Human Genet., 94, 665-670 (1994).
20. L. Del Senno, G. L. Aguiari, and R. Piva, Dinucleotide repeat polymorphism in the human estrogen receptor (ESR) gene, Human Molec. Genet., 7, 354 (1992).
21. M. Keaveney, J. Klug, M. T. Dawson, P. V. Nestor, J. G. Neilan, R. C. Forde, and F. Gannon, Evidence for a previously unidentified upstream exon in the human oestrogen receptor gene, J. Molec. Endocrinol., 6, 111-115 (1991).
22. K. Grandien, Determination of transcription start sites in the human estrogen receptor gene and identification of a novel, tissue-specific, estrogen receptor-mRNA isoform, Molec. Cell Endocrinol, 116, 207-212 (1996).
23. K. F. H. Grandien, A. Berkenstam, S. Nilsson, and J. A. Gustafsson, Localization of DNase I hypersensitive sites in the human oestrogen receptor gene correlates with the transcriptional activity of two differentially used promoters, J. Molec. Endocrinol., 10, 269-277 (1993).
24. K. Grandien, M. Backdahl, O. Ljunggren, J. A. Gustafsson, and A. Berkenstam, Estrogen target tissue determines alternative promoter utilization of the human estrogen receptor gene in osteoblasts and tumor cell lines, Endocrinology, 736, 2223-2229 (1995).
25. R. K. Ross and D. Schottenfeld, Prostate cancer, in Cancer Epidemology and Prevention, 2nd ed. (F. Fraumeni, ed.), Oxford University Press, Oxford, 1996, pp. 1180-1206.
26. R. K. Ross, L. Bernstein, H. Judd, R. Hanisch, M. C. Pike, and B. E. Henderson, Serum testosterone levels in young black and white men, J. Natl. Cancer Inst., 76, 45-48 (1986).
27. R. K. Ross, L. Bernstein, R. A. Lobo, H. Shimizu, F. Z. Stanczyk, M. C. Pike, and B. E. Henderson, 5-Alpha-reductase activity and risk of prostate cancer among Japanese and U.S. white and black males, Lancet, 339, 887-889 (1992).
28. A. E. Thigpen, D. L. Davis, T. Gautier, J. Imperato-McGinley, and W. Russell, The molecular basis of steroid 5-alpha-reductase deficiency in a large Dominican kindren, N. Engl. J. Med., 327, 1216-1219 (1992).
29. D. L. Davis and D. W. Russell, Unusual length polymorphisms in human steroid 5-α-reductase type 2 gene (SRD5A2), Human Molec. Genet., 2, 820 (1993).
30. J. K. V. Reichardt, N. Makridakis, B. E. Henderson, M. C. Yu, M. C. Pike, and R. K. Ross, Genetic variablity of the human SRD5A2 gene: Implications for prostate cancer risk, Cancer Res., 55, 3973-3975 (1995).
31. N. Makridakis, R. K. Ross, M. C. Pike, L. Chang, F. Z. Stanczyk, L. N. Kolonel, C. Y. Shi, M. C. Yu, B. E. Henderson, and J. K. V. Reichardt, A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase, Cancer Res., 57, 1020-1022 (1997).
32. G. Jenster, H. A. G. M. Van der Korput, C. Van Vroonhoven, T. H. Van der Kwast, J. Trapman, and A. O. Brinkmann, Domains of human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization, Molec. Endocrinol., 5, 1396-1404 (1991).
33. A. R. La Spada, E. M. Wilson, D. B. Lubahn, A. E. Harding, and K. H. Fischback, Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy, Nature, 352, 77-79 (1991).
34. A. N. Mhatre, M. A. Trifiro, M. Kaufman, P. Kazemi-Esfarjani, D. Figlewicz, G. Rouleau, and L. Pinsky, Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy, Nature Genet., 5, 184-188 (1993).
35. A. Edwards, H. A. Hammond, L. Jin, C. T. Caskey, and R. Chakraborty, Genetic variation at five trimeric and tandem repeat loci in four human population groups, Genomics, 12, 241-253 (1992).
36. R. A. Irvine, M. C. Yu, R. K. Ross, and G. A. Coetzee, The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer, Cancer Res., 55, 1937-1940 (1995).
37. S. A. Ingles, R. K. Ross, M. C. Yu, R. A. Irvine, G. LaPera, R. W. Haile, and G. A. Coetzee, Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor, J. Natl. Cancer Inst., 89, 166-170 (1997).
38. J. L. Stanford, J. J. Just, M. Gibbs, K. G. Wicklund, C. L. Neal, B. A. Blumenstein, and E. A. Ostrander, Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk, Cancer Res., 57, 1194-1198 (1997).
39. E. Giovannucci, M. J. Stampfer, K. Krithivas, M. Brown, A. Brufsky, J. Talcott, C. H. Hennekens, and P. W. Kantoff, The CAG repeat within the androgen receptor gene and its relationship to prostate cancer, Proc. Natl. Acad. Sci. USA., 94, 3320-3323 (1997).